What Happens When Colonoscopy Prep Fails: The Hidden Cost of Inadequate Bowel Preparation
Picture a screening colonoscopy that goes exactly as scheduled. The patient shows up on time, the physician is skilled, the equipment is state of the art. And the exam still fails, because the colon was not clean enough to see. No alarm sounds in that moment. The cost shows up later, in a missed lesion, a repeated procedure, a stranded slot on next month's schedule. Inadequate bowel preparation is one of the quietest and most expensive quality problems in gastroenterology, and it rarely gets named as the culprit it is.
How common is inadequate bowel preparation?
More common than most patients realize. Across real-world studies, 15% to 35% of colonoscopies are performed with inadequate or suboptimal bowel preparation. In routine practice, that puts somewhere between one in seven and one in three procedures in a compromised position before the scope is even advanced.
The burden lands unevenly. Inadequate prep shows up more often in older adults, patients with diabetes or chronic constipation, those on medications that slow gastrointestinal motility, and anyone managing the regimen without clinical support. Many of those same patients carry elevated colorectal cancer risk, which is what turns a preparation problem into a detection problem.
What a failed prep does to the exam
Everything a colonoscopy accomplishes depends on visualization, and residual stool takes that away. The lesions most likely to hide behind it are the small, flat, and right-sided polyps that are already the toughest to catch.
The numbers make the stakes concrete. In a study of patients with inadequate bowel preparation on screening colonoscopy, the per-adenoma miss rate reached 47.9%. Close to half of the adenomas that were present went undetected on the first exam. For a procedure whose entire purpose is finding and removing precancerous polyps, that is the difference between prevention and a missed window.
The cost to patients
For the patient, a failed prep usually means doing the whole thing over. Quality guidelines call for repeating colonoscopy within one year when preparation is inadequate, which translates into a second round of the most-dreaded part of the process, another day away from work, and another recovery.
The damage is not only logistical. Patients who have already been through colonoscopy report greater aversion to the prep than those who never have, so a do-over makes the next screening less likely, not more. A failed prep today quietly raises the odds of an avoided screening tomorrow.
The cost to physicians and clinics
Long before it becomes a repeat procedure, poor prep is an operational tax. It stretches scope time, raises staff and anesthesia utilization, and clogs the endoscopy schedule. When the colon is too dirty to proceed safely, the case converts to a same-day cancellation, and a procedure slot that cannot be refilled on short notice is simply lost.
Those disruptions stack on top of an already fragile schedule. Cancellations and no-shows are endemic in endoscopy, and prep is one of the few drivers a practice can actually do something about. A large share of lost capacity is set in motion before the patient ever walks through the door.
The cost to payers and the system
Zoom out, and the pattern is that the system pays for the same screening twice. Every prep-driven repeat is a duplicated cost: another facility fee, another physician fee, another round of anesthesia and pathology. Spread across a screening program meant to save money by preventing cancer, those duplicates add up to real erosion.
There is even a point where the arithmetic flips. Modeling suggests screening colonoscopy stops being cost-effective relative to other strategies once more than roughly 13% of exams must be repeated for inadequate preparation. Set that 13% threshold against real-world inadequate-prep rates of 15% to 35%, and a lot of practices are operating right at the edge where screening economics start to come apart.
A structural problem, not a patient failure
It would be easy to read all of this as patients not trying hard enough. The evidence points somewhere else. The prep model itself has barely changed in decades. It still asks people to carry out a complex medical preparation at home, alone, with no way to confirm the result until the procedure is underway. When the quality of a clinical input rides entirely on unsupervised self-administration, variability is not a risk, it is the expected outcome. That is precisely what surfaces as inadequate prep.
The gap between intent and result is well documented. Quality programs commonly target adequate preparation in 90% or more of cases, yet baseline performance routinely falls short, which is the clearest sign that the problem is built into the process rather than the person.
Closing the gap at the source
If unsupervised, at-home execution is the largest source of variability, the most direct fix is to remove it. That is the thinking behind ZeraFlow, the clinic-based bowel preparation system we are developing at Zera Medical. Instead of a multi-day regimen managed at home, the patient takes a few mild laxative tablets the night before and completes a short, nurse-supervised warm-water cleanse at the clinic immediately before colonoscopy. In a published clinical study of 125 patients, 89.4% achieved good or excellent bowel preparation and median preparation time was 33 minutes, with zero device-related serious adverse events. Standardize the step that fails most often, and patients can arrive consistently ready.
ZeraFlow is currently pursuing FDA 510(k) clearance and is not yet available in the United States.
What this adds up to
Inadequate bowel preparation is not a footnote in the screening process. It misses lesions, sends patients back for repeats, destabilizes clinic schedules, and inflates cost across the system, all from a step that takes place before the colonoscopy even begins. The hopeful part is that of all the things that can go wrong in colorectal screening, this is among the most fixable. Get the prep right, and the procedure can finally do what it was designed to do.
Better prep. Better procedures.
This post is part of an ongoing series from Zera Medical on the colorectal cancer screening gap and the preparation experience that shapes it. Zera Medical is developing ZeraFlow™, a clinic-based bowel preparation system. ZeraFlow™ has not been cleared by the FDA and is not available for commercial use or sale in the United States. This device is currently under FDA review and is not available in all markets.